OBR Daily Commentary

forumImage

Oncologists Getting 6% of Drug Price Is 'Financial Conflict'

(Medscape Medical News) Mar 7, 2018 - "No one is immune from $ temptation.... We have a system that rewards oncologists and their chemotherapy offices with more $ for giving more expensive chemo. This has to change," said Vincent Rajkumar, MD, a professor of medicine and a hematologist/oncologist at the Mayo Clinic, Rochester, Minnesota.

Read Article arrow

Jeff Patton, M.D. (Posted: March 07, 2018)

quotesThere are certainly some perverse incentives in medicine but there is a significant literature that community oncologist "who own their own infusion suites" prescribe the same medications even if the financial incentives are removed. There is also published literature, that institutions like the Mayo Clinic that are enrolled in the 340B government discount program where there financial incentives are 40-50% not 6%, prescribe more expensive therapies than their colleagues in the community. Dr. Rajkumar lives in a glass house and should check the facts before impugning others.quotes

Add Comment 3 Comment
forumImage

New Mexico Physician Chosen as AMA President-elect

(AMA) June 13, 2017 - Physicians gathered at the Annual Meeting of the American Medical Association (AMA) today voted for Barbara L. McAneny, M.D., an oncologist from Albuquerque, N.M., as the new president-elect of the nation’s premier physician organization. Following a year-long term as president-elect, Dr. McAneny will assume the office of AMA president in June 2018.

Read Article arrow

Jeff Patton, M.D. (Posted: June 14, 2017)

quotesThis is great news for community oncology. Barbara will be a great champion for us and the value we bring to our patients and our community. Congratulations Barbara!quotes

Add Comment 1 Comment
forumImage

Genentech’s Shocking $2 Billion 340B Revelation

(Drug Channels) Nov 15, 2016 - ICYMI, the Roche Group recently made a startling disclosure: For the first half of 2016, the 340B Drug Pricing Program accounted for 18% of Genentech’s volume.

Read Article arrow

Jeff Patton, M.D. (Posted: November 15, 2016)

quotesGood for Genentech! The abuse of this program needs to end ASAP. I agree with the author and hope that the new administration will take a close look at this program and bring it back to the initial and laudable intent and away from current abuses.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...